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        The development of B lymphocytes from plu-
ripotent progenitors is a tightly regulated pro-
cess that occurs in hemopoietic tissues, primarily 
embryonic liver and bone marrow in mammals 
(  1  ). In these sites, lymphoid progenitors lack-
ing Ig expression (pro-B cells) give rise to large 
B lymphocyte precursors (preB cells) expressing 
     heavy chains (    HCs) (  2  –  5  ) as a result of 
    HC V(D)J gene rearrangements. A key check-
point in B cell lineage development is the ability 
of the newly generated     HC to associate with 
the surrogate light chain (SLC) composed of 
VpreB and     5/14.1 and homologous to the V 
and C regions of LCs (  6, 7  ). SLC binds nascent 
    HC proteins, thereby releasing them from 
BiP-mediated retention in the endoplasmic re-
ticulum (  8  –  9  ). SLC/    HC homodimers then 
associate with Ig    /Ig     heterodimeric signal-
transducing elements to form the preB cell 
receptor (BCR), which is exported from the 
Golgi apparatus to the preB cell surface in the 
context of lipid rafts, where they associate with 
signaling elements such as Syk, Lyn, Btk, and B 
cell linker (BLNK). Signaling through the pre-
BCR leads to a transient cellular proliferation 
and the V-J  L   rearrangement of the      or      LCs 
(  10  –  12  ). Successful VJ  L   rearrangement allows 
the assembly of BCRs composed of     HC, LC, 
and Ig    /Ig     on newly generated immature 
IgM-expressing B cells (  13  –  14  ), which then 
exit the bone marrow and complete their mat-
uration in the secondary lymphoid organs. 
  The crucial role of preBCR signaling dur-
ing early B lineage diff  erentiation is indicated 
by the block in pro-B to preB cell diff  erentia-
tion in mice and man with defi  ciencies in single 
preBCR components or in the essential down-
stream signaling elements (  15  –  20  ). 
  Mutations of   BTK  , which is the gene re-
sponsible for X-linked agammaglobulinemia, 
account for     85% of cases with agammaglobu-
linemia and absent circulating B cells (  21  ). The 
remaining 15% of patients constitute a hetero-
geneous group, including patients with muta-
tions in     HC,     5, Ig    , and BLNK, which are 
the genes responsible for the autosomal recessive 
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  Agammaglobulinemia is a rare primary immunodefi  ciency characterized by an early block 
of B cell development in the bone marrow, resulting in the absence of peripheral B cells and 
low/absent immunoglobulin serum levels. So far, mutations in Btk,      heavy chain, surrogate 
light chain, Ig    , and B cell linker have been found in 85  –  90% of patients with agamma-
globulinemia. We report on the fi  rst patient with agammaglobulinemia caused by a homo-
zygous nonsense mutation in Ig    , which is a transmembrane protein that associates with 
Ig     as part of the preBCR complex. Transfection experiments using   Drosophila melanogaster   
S2 Schneider cells showed that the mutant Ig     is no longer able to associate with Ig    , 
and that assembly of the BCR complex on the cell surface is abrogated. The essential role 
of Ig     for human B cell development was further demonstrated by immunofl  uorescence 
analysis of the patient  ’  s bone marrow, which showed a complete block of B cell develop-
ment at the pro-B to preB transition. These results indicate that mutations in Ig     can 
cause agammaglobulinemia in man. 2048 Ig     DEFICIENCY IN HUMANS | Ferrari et al.
healthy parents without known consanguinity. He has two 
healthy sisters, and no positive family history for primary 
immunodefi  ciencies is present in the pedigree. The pregnancy 
and delivery were uneventful. At the age of 8 mo, the patient 
was hospitalized because of pneumonia of the left lobe and 
  Salmonella  -caused enteritis. Immunological work up showed 
a marked hypogammaglobulinemia (IgG, 100 mg/d; IgA and 
IgM, undetectable) and absence of peripheral CD19-positive 
cells (1%), in the presence of normal numbers of T and NK 
cells; T cell function, assessed by mitogen-induced prolifera-
tion, was normal. Intravenous immunoglobulin replacement 
therapy was initiated at the age of 8 mo. During follow up, 
despite appropriate immunoglobulin substitution therapy, the 
patient suff  ered several episodes of bacterial conjunctivitis, 
acute otitis media, sinusitis, and bronchitis. A computed tomog-
raphy scan of the nasal sinuses showed a pattern compatible 
with chronic sinusitis, whereas no bronchiectasis was observed. 
  BTK   gene sequence analysis was normal. 
  Genomic DNA from this patient was analyzed by PCR 
amplifi  cation and direct sequencing of exons and exon  – 
intron junctions of genes encoding for the preBCR compo-
nents. We found a homozygous C    T nucleotide substitution in 
exon 3 of the   B29   gene, encoding for the Ig     protein (  Fig. 1  ), 
at position c.238 (GenBank accession no.   M89957  ) corre-
sponding to amino acid 80. The mutation causes the replace-
ment of Gln80 with a stop codon within the extracellular 
immunoglobulin domain of Ig    , preventing the expression 
of the functional transmembrane protein and possibly inter-
fering with the assembly of the preBCR on cell surface.   
  Both parents of the patient were heterozygous for this 
mutation. The Gln80X mutation was not detected in DNA 
samples obtained from 90 healthy controls; in addition, 
forms of agammaglobulinemia. However, mutations in these 
genes do not account for all patients with selective defect of 
B cell development, suggesting that mutations in other, yet 
to be identifi  ed genes may aff  ect early B cell development. 
Regardless of the genetic defect, patients with a selective 
arrest of B cell development are characterized by early onset 
of severe bacterial infections as a result of their inability to 
mount an antibody response. 
  To better clarify the nature of genetic defects that results 
in abnormal B cell development in man, we screened patients 
with early-onset hypogammaglobulinemia and absent circu-
lating B cells for mutations in genes that are expressed in the 
early stages of B cell diff  erentiation. 
  We have identifi  ed one patient with a homozygous de-
fect in the Ig    -encoding gene, and have compared the pe-
ripheral B cell phenotype of this patient with that of patients 
with defects in the     HC or Btk. Transfection experiments 
using   D. melanogaster   S2 Schneider cells demonstrated that 
the mutation in Ig     abrogates the assembly of the BCR on 
the cell surface. Bone marrow studies showed that the muta-
tion causes a complete block in B cell development at the 
pro-B to preB transition, a phenotype resembling that ob-
served in Ig    -null mice (  22  ). 
    RESULTS AND DISCUSSION   
  Mutation of the Ig     gene causes agammaglobulinemia 
  As part of an ongoing eff  ort to extensively genotype agam-
maglobulinemic patients for known and candidate genes 
causing agammaglobulinemia (  23  ), we found for the fi  rst 
time a homozygous mutation in the Ig    -encoding gene in 
a patient clinically diagnosed with agammaglobulinemia. 
The patient, a 20-yr-old Italian male, is the fi  rst-born child of 
  Figure 1.     Mutation analysis of the   B29   gene. (A) Electropherograms from a portion of exon 3 showing the 238 C    T mutation at the base corre-
sponding to amino acid 80 of the Ig     chain, compared with the wild-type sequence from a healthy donor (WT). The sequences obtained from hetero-
zygous parents (I.1 and I.2) are shown. (B) Schematic representation of Ig   -encoding  gene.   JEM VOL. 204, September 3, 2007  2049
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CD22 at lower levels compared with healthy controls (un-
published data). The CD22  lo   subset was poorly represented 
(    1%) in 25 healthy controls, whereas in patients CD22  lo   
cells range from 2 to 4.5% of the gated lymphocytes. 
  The CD22  lo   cells did not express either the pan  –  B cell 
marker CD19 or the early B cell marker CD10; because the 
CD22 molecule was previously found expressed in human 
basophiles (  25  ), we tested if the CD19  −  /CD22  lo   population 
in agammaglobulinemic patients was accounted for by baso-
philes. This turned out to be the case, as demonstrated by 
Toluidine blue staining of the sorted CD22  lo   cells, showing 
pure basophiles with typical large, dark granules. Furthermore, 
the CD22  lo   cells were positive for CD13, which is a myelo-
monocytic lineage marker (unpublished data). Therefore, the 
CD22  lo   cell population from the Ig    -defi  cient patient did not 
belong to the B lineage. 
  To determine at which stage B cell development is blocked, 
bone marrow cells from the patient and an age-matched con-
trol were evaluated by cytofl  uorimetric analysis. CD19+ B 
cells were markedly reduced in the patient (    1%) when com-
pared with the healthy control (    10%) (  Fig. 3  ).   Two-color 
immunofl  uorescence was used to defi  ne the percentages of 
pro-B cells (CD34	CD19  
  ) and preB/immature B cells 
(CD34  
  CD19	). The coexpression of CD19 and CD34 
showed that     85% of the patient  ’  s B cells belong to the pro-B 
sequence analysis of the whole   B29   gene reveals the presence 
of a common haplotype represented by a T    C silent change 
at codon 122 in cis with a 3    -untranslated region T    C tran-
sition, which is present at a high frequency (f  CC   = 0.76) in 
the 90 controls. Our patient is homozygous for the less com-
mon 122/T and 3    -untranslated region /T haplotype, sug-
gesting the possibility of a founder eff  ect for the mutated 
allele. Although not reported, consanguinity of patient  ’  s parents 
cannot be excluded. 
  Reconstitution of the BCR in S2 cells 
  It has been shown that effi   cient transport of IgM to the cell 
surface requires coexpression of Ig    ; furthermore, IgM and 
Ig     alone are suffi   cient to reconstitute antigen-specifi  c signal 
transduction by Ig     (  24  ). The eff  ect of the Gln80X Ig     mu-
tation on BCR assembly was assessed by a reconstitution ex-
periment in   Drosophila melanogaster   S2 cells. 
  The human Ig     cDNA was cloned in an appropriate ex-
pression vector, and   D. melanogaster   S2 cells were cotrans-
fected with mouse     1LC,     HC, FLAG-tagged Ig    , and 
either human wild-type Ig     or mutant Gln80X Ig    . After 
induction of expression of the recombinant proteins, cells were 
harvested and reconstitution of the IgM BCR was detected 
by staining with a phycoerythrin (PE)-conjugated anti-FLAG 
antibody that binds to Ig     and a biotinylated anti-IgM 
antibody. PE- and Cy5-conjugated streptavidin double-
positive cells indicate the expression of the BCR on the 
cell surface. 
    Fig. 2   shows that the wild-type human Ig     chain is as 
effi   cient as the mouse Ig     chain at promoting assembly of the 
IgM BCR complex on the cell membrane (compare the bot-
tom left and top right graphs).   On the contrary, insertion of 
the Gln80X mutation in Ig     prevents reconstitution of the 
IgM BCR on the cell surface, which is similar to expression 
of Ig     only (compare the bottom right and top left graphs). 
  S2 cells cotransfected with FLAG-tagged Ig     and wild-
type Ig     and stained with the PE-conjugated anti-FLAG 
antibody showed that the human Ig     alone was not able 
to carry Ig     to the cell surface, proving that, in the afore-
mentioned experiments, any Ig     chain detected at the S2 
cell surface is, indeed, part of the assembled BCR complex 
(unpublished data). 
  Immunofl  uorescence studies 
  PBMCs from the patient carrying the Ig     mutation, three 
patients with Btk defi  ciency, three patients with     HC defi  -
ciency, and three healthy controls were compared using standard 
fl  ow cytometry markers. The dramatic reduction of circulat-
ing B cells in the Ig    -defi  cient patient was confi  rmed using 
the typical B cell marker CD19 (unpublished data). As expected, 
PBMCs from the patient, as well as PBMCs from patients 
with mutations in Btk and     HC, did not express mature IgM 
on the cell surface (unpublished data). 
  The analysis of the alternative pan  –  B cell marker CD22 in 
the Ig    -defi  cient patient, as well as in Btk- and     HC-defi  cient 
patients, revealed the presence of a cell population expressing 
  Figure 2.     Surface expression of the IgM BCR in S2 cells. S2 cells 
were cotransfected with plasmids encoding for EGFP, mouse    HC,    1  LC, 
Ig    , and different Ig     chains, as indicated. After 5 h, expression cells were 
harvested and stained with PE-labeled anti-FLAG antibody and biotinyl-
ated anti-IgM antibody, followed by streptavdin-Cy5, to detect Ig     and 
membrane IgM, respectively. Cells were gated for EGFP-positive cells to 
normalize the transfection effi   ciency.   2050 Ig     DEFICIENCY IN HUMANS | Ferrari et al.
lacking the transmembrane domain because of premature 
termination; however, it is also possible that the occurence 
of a premature stop codon causes nonsense-mediated RNA 
decay. In any event, the mutation in Ig     prevents the assem-
bly of the IgM BCR on the cell surface, as demonstrated by 
the reconstitution experiment shown in   Fig. 2  . 
  The preBCR checkpoint is essential for B cell develop-
ment. So far, animal models defi  cient for diff  erent preBCR 
components were shown to have an arrest at the pro-B to 
preB cell stage of development, although some models pre-
sented a leaky phenotype (e.g., the presence of peripheral B 
cells in     5-defi  cient mice [reference   26  ]). Human mutations 
in preBCR components further elucidated the role of the 
preBCR complex in B cell development, and underlined that 
animal models are not always concordant with the phenotype 
of patients carrying mutations in the same gene; the afore-
mentioned human     5 defi  ciency presents a severe defect in B 
cells, with absence of peripheral B cells. On the other hand, 
human Ig     defi  ciency closely resembles the phenotype ob-
served in knockout mice in that these mice have no mature 
peripheral B cells and B cell development is blocked at the 
pro-B cell/preBI cell stage (  22  ). 
  In conclusion, this is the fi  rst report of a patient with agam-
maglobulinemia caused by a homozygous Gln80X mutation 
in Ig    , resulting in a stop codon that abrogates the expression 
of the preBCR complex on the cell surface. Bone marrow B 
cell analysis of the Ig    -defi  cient patient indicated an arrest at 
the pro-B  –  preB transition, a phenotype resembling the one 
observed in other known forms of agammaglobulinemia. 
    MATERIALS AND METHODS   
  Genetic analysis.     Genomic DNA was extracted from peripheral blood leu-
kocytes using standard techniques. Exons and exon  –  intron junctions were 
amplifi  ed by PCR using FastStart Taq DNA Polymerase (Roche) under 
standard conditions. Purifi  ed PCR products were sequenced on both strands 
using a Big Dye Terminator v1.1 Cycle Sequencing kit (Applied Biosystems) 
and were run on an ABI 3730 Genetic Analyzer (Applied Biosystems). The 
primers used in this study are available upon request. The M89957 GenBank 
entry was used as reference sequence. 
  For the genetic diagnosis, the informed consent was signed by the patient. 
  DNA constructs.     For inducible expression of human Ig     in S2 cells, 
wild-type and mutant cDNAs were cloned into the S2 plasmid pRmHa-3 
containing a copper-inducible metallothionein promoter. Total RNA 
extracted from PBMC was amplifi  ed by RT-PCR using the following 
oligonucleotides: Ig    _cDNA-F 5    -GGTCGGGGACAGAGCAG-3     and 
Ig    _cDNA-R 5    -CGACCTGGCTCTCACTCCT-3    , and the correspond-
ing PCR fragment was subcloned into the pRmHa-3 plasmid. The C    T 
single-nucleotide substitution was introduced into the Ig     cDNA by site-
directed mutagenesis. 
  Reconstitution of IgM-BCR in S2 cells.       D. melanogaster   S2 Schneider 
cells were grown in Schneider  ’  s   Drosophila   medium (Life Technologies, Inc.) 
supplemented with 5  –  10% FCS at 27  °  C with atmospheric CO  2   levels. Tran-
sient transfection of S2 cells and induction of expression (5 h) was performed 
as previously described in Wossning et al. (  27  ). For FACS analysis, cells were 
stained with anti-FLAG PE antibody and biotinylated anti-IgM antibody, 
followed by Cy5-conjugated streptavidin. To normalize the transfection 
effi   ciencies, S2 cells were cotransfected with the vector pDEGFP containing 
the enhanced GFP (EGFP) coding sequence. 
stage of diff  erentiation, whereas     5% of the healthy control  ’  s 
B cells presented the pro-B phenotype. These fi  ndings indi-
cate a block of B cell development at the transition from the 
pro-B to preB stage. 
  To further characterize the point of arrest of B cell develop-
ment, expression of TdT and surface Ig were evaluated. Remark-
ably, the Ig    -defi  cient patient presented an accumulation of 
TdT-positive cells that did express CD19. Furthermore, no 
surface immunoglobulin expression could be detected on the 
patient  ’  s B cells. These results further confi  rm that the arrest 
of B cell development in the Ig    -defi  cient patient occur at 
the pro-B to preB transition; a similar block at the pro-B stage 
has been described in patients aff  ected by mutations of other 
members of the preBCR complex, i.e.,         HC defi  ciency (  23  ) 
and Ig     defi  ciency (  19  ). Unfortunately, we were unable to 
perform further biochemical and functional analyses, such as 
assessment of the extent of V(D)J recombination, because 
of the low number of bone marrow lymphocyte precursors 
obtained from the patient biopsy. 
  In principle, the occurrence of a stop codon in the N-
terminal portion of Ig     could result in a truncated protein 
  Figure 3.     Cytofl  uorimetric analysis of B cell development. Bone mar-
row mononuclear cells from the Ig   -defi  cient patient and an age-matched 
healthy control were stained for surface CD19, CD34, Ig, and intracellular 
TdT. The patient showed a marked reduction in the number of CD19	 cells 
within the lymphoid gate, and     85% of the B-lineage cells were positive 
for CD34 (top row). Virtually none of the CD19+ cells from the Ig   -defi  cient 
patient were B cells, as defi  ned by the coexpression of CD19 and surface 
immunoglobulin (middle row). Permeabilized cells were stained for cytoplas-
mic TdT. The majority of the CD19+ cells from the patient were pro-B cell 
precursors, as defi  ned by coexpression of CD19 and TdT (bottom row).    JEM VOL. 204, September 3, 2007  2051
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  Cytofl  uorimetric analysis.     PBMCs from fresh blood samples and bone 
marrow MCs from patients and healthy controls were isolated by Ficoll-
Hypaque gradient centrifugation and stained with the following conjugated 
anti  –  human monoclonal antibodies: FITC-labeled anti  –  human CD19, PE-
labeled anti  –  human CD22, PE-labeled anti  –  human CD34, PE-labeled anti  –
  human surface Ig, and PE-labeled anti  –  human TdT. Cells were resuspended 
in PBS and 0.1% BSA at the concentration of 5      10  5    –  1      10  6   cells/ml, and 
then stained with and the anti  –  human antibodies using standard protocols. 
Stained cells were washed twice with PBS/BSA and analyzed with a FACS-
Calibur fl  ow cytometer (Becton Dickinson). 
  The human experiments have been approved by the hospital Ethical 
Committee of Spedali Civili of Brescia. 
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